Switch theme
Sign up to access all valuation multiples
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
2003
n/a
LTM Revenue $451M
LTM EBITDA $134M
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Betta Pharmaceuticals has a last 12-month revenue of $451M and a last 12-month EBITDA of $134M.
In the most recent fiscal year, Betta Pharmaceuticals achieved revenue of $338M and an EBITDA of $93.8M.
Betta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Betta Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $338M | $418M | XXX | XXX | XXX |
| Gross Profit | $285M | $290M | XXX | XXX | XXX |
| Gross Margin | 84% | 69% | XXX | XXX | XXX |
| EBITDA | $93.8M | $120M | XXX | XXX | XXX |
| EBITDA Margin | 28% | 29% | XXX | XXX | XXX |
| Net Profit | $52.8M | $20.0M | XXX | XXX | XXX |
| Net Margin | 16% | 5% | XXX | XXX | XXX |
| Net Debt | n/a | $42.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Betta Pharmaceuticals's stock price is CNY 54 (or $7).
Betta Pharmaceuticals has current market cap of CNY 22.7B (or $3.1B), and EV of CNY 24.2B (or $3.3B).
See Betta Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $3.1B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Betta Pharmaceuticals has market cap of $3.1B and EV of $3.3B.
Betta Pharmaceuticals's trades at 7.4x LTM EV/Revenue multiple, and 24.8x LTM EBITDA.
Analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Betta Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.3B | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | 27.8x | XXX | XXX | XXX |
| P/E | 43.3x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBetta Pharmaceuticals's NTM/LTM revenue growth is 25%
Betta Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Betta Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Betta Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 54% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 70% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Betta Pharmaceuticals acquired XXX companies to date.
Last acquisition by Betta Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Betta Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Betta Pharmaceuticals founded? | Betta Pharmaceuticals was founded in 2003. |
| Where is Betta Pharmaceuticals headquartered? | Betta Pharmaceuticals is headquartered in China. |
| Who is the CEO of Betta Pharmaceuticals? | Betta Pharmaceuticals's CEO is Mr. Lieming Ding. |
| Is Betta Pharmaceuticals publicy listed? | Yes, Betta Pharmaceuticals is a public company listed on SHE. |
| What is the stock symbol of Betta Pharmaceuticals? | Betta Pharmaceuticals trades under 300558 ticker. |
| When did Betta Pharmaceuticals go public? | Betta Pharmaceuticals went public in 2016. |
| Who are competitors of Betta Pharmaceuticals? | Similar companies to Betta Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Betta Pharmaceuticals? | Betta Pharmaceuticals's current market cap is $3.1B |
| What is the current revenue of Betta Pharmaceuticals? | Betta Pharmaceuticals's last 12-month revenue is $451M. |
| What is the current EBITDA of Betta Pharmaceuticals? | Betta Pharmaceuticals's last 12-month EBITDA is $134M. |
| What is the current EV/Revenue multiple of Betta Pharmaceuticals? | Current revenue multiple of Betta Pharmaceuticals is 7.4x. |
| What is the current EV/EBITDA multiple of Betta Pharmaceuticals? | Current EBITDA multiple of Betta Pharmaceuticals is 24.8x. |
| What is the current revenue growth of Betta Pharmaceuticals? | Betta Pharmaceuticals revenue growth between 2023 and 2024 was 24%. |
| Is Betta Pharmaceuticals profitable? | Yes, Betta Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
